Agios Reports Second Quarter 2015 Financial Results and Provides Updates on Clinical Development Progress

Agios Reports Second Quarter 2015 Financial Results and Provides Updates on Clinical Development Progress

August 6, 2015

Global Phase 3 Registration-enabling Studies on Track to Begin in Second Half of 2015 for AG-221 & First Half of 2016 for AG-120

Phase 1 Expansion Studies for AG-221 & AG-120 Programs Ongoing

CAMBRIDGE, Mass., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today reported business highlights and financial results for the second quarter ended June 30, 2015.

Editas Medicine Named A 2015 Technology Pioneer by World Economic Forum

Editas Medicine Named A 2015 Technology Pioneer by World Economic Forum

August 5, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Editas Medicine, a leading genome editing company, today announced that it has been selected as a 2015 Technology Pioneer by the World Economic Forum. Editas is among 49 companies being recognized with this distinguished award for advancing the world’s most innovative technologies.

T2 Biosystems Reports 2015 Second Quarter Results

T2 Biosystems Reports 2015 Second Quarter Results

August 4, 2015

LEXINGTON, Mass., Aug. 4, 2015 (GLOBE NEWSWIRE) -- T2 Biosystems (NASDAQ:TTOO) today reported operating highlights and financial results for the second quarter ended June 30, 2015. Recent operational highlights included:

Concert Pharmaceuticals Reports Second Quarter 2015 Financial Results and Provides Company Update

Concert Pharmaceuticals Reports Second Quarter 2015 Financial Results and Provides Company Update

August 5, 2015

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2015. “We are pleased with the continued progress of our pipeline over the last quarter. In particular, we are encouraged by the progress Avanir has made with AVP-786 in 2015.

National Institute of Nursing Research Uses Quanterix’s Simoa Technology to Identify the Significance of Key Protein in Long-term Complications Caused by Traumatic Brain Injury

National Institute of Nursing Research Uses Quanterix’s Simoa Technology to Identify the Significance of Key Protein in Long-term Complications Caused by Traumatic Brain Injury

August 3, 2015

Study identifies the correlation of tau accumulation in military personnel to those who experienced long-term neurological symptoms after a TBI; findings to be used to identify patients who are most at risk

Quanterix Named Final Winner of NFL and GE Head Health Challenge I

Quanterix Named Final Winner of NFL and GE Head Health Challenge I

July 23, 2015

GE and the NFL award Quanterix with $500,000 grant to fund advancements in measuring the long-term effects of brain injury in athletes using its Simoa technology

Denali Therapeutics Appoints Carole Ho, M.D., as Chief Medical Officer and Head of Development

Denali Therapeutics Appoints Carole Ho, M.D., as Chief Medical Officer and Head of Development

July 22, 2015

SOUTH SAN FRANCISCO, Calif., July 22, 2015 /PRNewswire-USNewswire/ -- Denali Therapeutics Inc. ("Denali"), a biotechnology company focused on developing effective therapies for neurodegenerative diseases, announced today that Carole Ho, M.D., has joined the company as Chief Medical Officer and Head of Development. In this role, Dr. Ho will lead the translational and clinical development activities at Denali and serve on the Executive Leadership Team.

Joule Appoints Peter Matrai CFO, Biofuels industry veteran brings expertise in commercialization of new technologies

Joule Appoints Peter Matrai CFO, Biofuels industry veteran brings expertise in commercialization of new technologies

July 22, 2015

Bedford, Mass -- Joule, the pioneer of liquid fuels from recycled CO2, today announced the appointment of Peter Matrai as Senior Vice President and Chief Financial Officer. He joins the company with nearly 20 years of experience in finance, global strategy and corporate development, including a decade spent in the biofuels sector for BP.

Red Rock Reaches Agreement with FedEx Express to Provide Biofuels for Renewable, Low-Carbon Jet Fuel

Red Rock Reaches Agreement with FedEx Express to Provide Biofuels for Renewable, Low-Carbon Jet Fuel

July 21, 2015

FORT COLLINS, Colo.--(BUSINESS WIRE)--Red Rock Biofuels LLC, a pioneer in renewable biofuels, announced today that it will produce approximately three million gallons of low-carbon, renewable jet fuel per year for FedEx Express, a subsidiary of FedEx Corp. (NYSE:FDX). The agreement runs through 2024, with first delivery expected in 2017. FedEx joins Southwest Airlines in purchasing Red Rock’s total available volume of jet fuel.

Editas Medicine Appoints Andrew Hack, M.D., Ph.D., as Chief Financial Officer

Editas Medicine Appoints Andrew Hack, M.D., Ph.D., as Chief Financial Officer

July 1, 2015

-- Experienced Healthcare Finance Leader Joins Leadership Team to Help Drive Continued Growth --

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Editas Medicine, a leading genome editing company, today announced the appointment of Andrew Hack, M.D., Ph.D., as chief financial officer. Dr. Hack brings to Editas a deep understanding of capital markets, strong relationships across the financial community and more than a decade of experience analyzing the successes and failures of biopharmaceutical companies.